OWLT - Owlet, Inc.
NYSE
->
Healthcare
->
Medical Devices
Lehi,
United States
Type: Equity
OWLT price evolution
OWLT
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $13.97 | $9.4 | $12.98 | $15.39 |
| Inventory | $6.49 | $11 | $12.39 | $14.74 |
| Total current assets | $39.94 | $37.5 | $51.75 | $59.86 |
| Long term investments | ||||
| Property, plant & equipment | $1.31 | $1.8 | $2.25 | $2.76 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $44.12 | $42.3 | $57.26 | $65.93 |
| Current liabilities | ||||
| Accounts payable | $13.68 | $18.4 | $22.76 | $30.84 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $45.09 | $41.1 | $48.38 | $50.72 |
| Long term debt | $0.5 | $2 | $3.5 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $73.8 | $67.3 | $78.99 | $81.89 |
| Shareholders' equity | ||||
| Retained earnings | -$255.66 | -$248.7 | -$243.09 | -$234.63 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.29 | |||
| Short term investments | ||||
| Net receivables | $13.97 | $16 | $10.5 | $10.53 |
| Inventory | $6.49 | $18.5 | $18 | $7.91 |
| Total current assets | $39.94 | $51.3 | $135.8 | $1.56 |
| Long term investments | ||||
| Property, plant & equipment | $1.31 | $3.4 | $1.9 | $1.72 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $44.12 | $58.1 | $140 | $231.61 |
| Current liabilities | ||||
| Accounts payable | $13.68 | $30.4 | $27.8 | $16.38 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $45.09 | $66.6 | $69.1 | $0.32 |
| Long term debt | $8 | $10.18 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $73.8 | $68.7 | $84.8 | $31.9 |
| Shareholders' equity | ||||
| Retained earnings | -$255.66 | -$222.76 | -$143.42 | -$8.25 |
| Other shareholder equity | -$10.6 | $55.2 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 29 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $17.36 | -$2.5 | ||
| Cost of revenue | ||||
| Gross Profit | $4.61 | -$6 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $26.43 | $27.3 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.01 | |||
| Interest expense | -$0.42 | -$0.4 | ||
| Net income | ||||
| Net income | -$19.36 | -$24 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $75.8 | $49.8 | ||
| Cost of revenue | ||||
| Gross Profit | $35 | $22.9 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $90.8 | $0.48 | $39.95 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$27.9 | -$7.19 | -$0.69 | |
| Net income | ||||
| Net income | -$71.7 | -$8.25 | -$17.85 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1.4 | -$1.24 | -$0.7 | -$2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.08 | -$0.9 | $1.78 | $120.6 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$71.88 | -$57.8 | -$26.32 | $78 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$2 | -$230 | -$1.96 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $120.6 | $231.74 | $12.46 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $78 | $1.29 | -$5.56 | |
News
Fundamentals
| Market cap | $33.96M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 8.80M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -44.90% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.89 |
| Quick ratio | 0.74 |